Jasdeep Sidana, MD
Pulmonary Disease · Orange, CTNPI 1558482075
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Boehringer Ingelheim at 50.6% of the total. Reporting peaked in 2019 at $8,253 and has fallen 81.5% since, to $1,529 in 2025.
Across 411 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- GSK$2K
- Genentech USA, Inc.$771
- AstraZeneca$705
- Sunovion Pharmaceuticals Inc.$625
- Novartis$396
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$5,53543%
- Food & beverage$7,19156%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 49 | $6,480 |
| GSK | 118 | $1,878 |
| Genentech USA, Inc. | 41 | $771 |
| AstraZeneca | 34 | $705 |
| Sunovion Pharmaceuticals Inc. | 57 | $625 |
| Novartis | 19 | $396 |
| Inspire Medical Systems, Inc. | 10 | $234 |
| Mylan Specialty L.p. | 11 | $199 |
| BD | 1 | $158 |
| Amgen(2 entities) | 7 | $147 |
| Regeneron Healthcare Solutions, Inc. | 6 | $141 |
| Pfizer | 8 | $139 |
| Viatris Specialty LLC | 11 | $136 |
| Grifols USA, LLC | 5 | $119 |
| 3b Medical, Inc. | 2 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Philips North America LLC | 5 | $78 |
| Verona Pharma, Inc. | 3 | $75 |
| Electromed, Inc. | 5 | $54 |
| Insmed, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Novo Nordisk | 2 | $34 |
| Mission Pharmacal Company | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Sanofi | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Merck | 1 | $14 |
| Echosens North America, Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$5,657
How this compares
$12,816 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Orange
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.